FATE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.68 USD | -3.16% |
|
0.00% | -1.60% |
| Jun. 07 | Fate Therapeutics, Inc. Appoints J. Scott Wolchko as Principal Financial and Accounting Officer | CI |
| May. 31 | Fate Therapeutics, Inc. Announces Chief Financial Officer Changes | CI |
Financials (USD)
| Sales 2024 * | 5.82M | Sales 2025 * | 5.39M | Capitalization | 419M |
|---|---|---|---|---|---|
| Net income 2024 * | -201M | Net income 2025 * | -222M | EV / Sales 2024 * | 32.6 x |
| Net cash position 2024 * | 229M | Net cash position 2025 * | 153M | EV / Sales 2025 * | 49.4 x |
| P/E ratio 2024 * |
-2.07
x | P/E ratio 2025 * |
-2.06
x | Employees | 181 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fate Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -3.16% | ||
| 1 month | -5.64% | ||
| 3 months | -54.68% | ||
| 6 months | +64.29% | ||
| Current year | -1.60% |
1 week
3.59
3.84
1 month
3.344.54
Current year
3.348.83
1 year
1.638.83
3 years
1.6397.43
5 years
1.63121.16
10 years
1.46121.16
| Managers | Title | Age | Since |
|---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 20-08-16 |
| Chairman | 75 | 11-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 58 | 14-03-16 |
Tim Coughlin
BRD | Director/Board Member | 57 | 13-07-31 |
| Chairman | 75 | 11-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.95% | 1 M€ | 0.00% | - | |
| 2.10% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 3.68 | -3.16% | 1,100,358 |
| 24-06-06 | 3.8 | +1.06% | 2,106,386 |
| 24-06-05 | 3.76 | +2.73% | 1,658,058 |
| 24-06-04 | 3.66 | -0.27% | 1,338,969 |
| 24-06-03 | 3.67 | -0.27% | 3,873,503 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
3.68
USD
Average target price
6.643
USD
Spread / Average Target
+80.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.60% | 419M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- FATE Stock
